Immunocore Holdings Plc Stock Price, News & Analysis

Immunocore presented initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress. The study evaluated the safety and antiviral activity of IMC-I109V, a T cell receptor bispecific targeting HBsAg. Initial results showed that a single low dose led to transient declines in HBsAg levels and ALT elevations, aligning with the drug's mechanism of action. No adverse events were reported, indicating a favorable safety profile. The trial aims for a functional cure for HBV, with a focus on further patient enrollment and dose escalation.

Immunocore has appointed Siddharth Kaul to its Board of Directors, effective June 8, 2022. Kaul, a seasoned finance expert with extensive life sciences experience, previously held significant roles at Novartis and Procter & Gamble. He will contribute as a Class II director and participate in the Audit and Remuneration committees. This appointment aligns with Immunocore's focus on the commercial rollout of its lead product, KIMMTRAK, for treating metastatic uveal melanoma and enhancing its oncology and infectious disease pipeline.

Immunocore Holdings has received marketing authorization for KIMMTRAK® (tebentafusp) from the UK, Australia, and Canada to treat unresectable or metastatic uveal melanoma. This therapy is the first approved treatment for this rare form of melanoma, displaying a statistically significant overall survival benefit in clinical trials. KIMMTRAK showed a median overall survival of nearly 22 months with a hazard ratio of 0.51. Following approvals in the US and EU, this new authorization marks a significant milestone for both the company and patients.

Immunocore presented new data on KIMMTRAK (tebentafusp-tebn) at the 2022 ASCO Annual Meeting. The Phase 1b trial showed a one-year overall survival (OS) of about 75% in heavily pre-treated metastatic cutaneous melanoma (mCM), surpassing the 55% benchmark. The study also confirmed that corticosteroids for adverse events did not significantly impact efficacy. Immunocore plans to initiate a randomized study by year-end to further evaluate tebentafusp in mCM.

Immunocore has entered a clinical trial collaboration with Sanofi to evaluate SAR444245, a PEGylated IL-2 candidate, in combination with KIMMTRAK for patients with metastatic cutaneous melanoma. The study is part of Sanofi's ongoing Phase 1/2 trial. Sanofi will handle clinical development costs, while Immunocore will supply KIMMTRAK. KIMMTRAK has FDA approval for unresectable or metastatic uveal melanoma, and upcoming trials are planned combining it with anti-PD1 therapy. This collaboration could enhance treatment prospects for patients with significant unmet needs.

Immunocore Holdings Plc (Nasdaq: IMCR) announced its participation in upcoming investor conferences. The company will present at the Jefferies Healthcare Conference on June 8, 2022, at 2:30 PM ET, and at the Goldman Sachs Global Healthcare Conference on June 15, 2022, at 4:00 PM PT. These presentations will be available for live webcasting on Immunocore’s website, with replays accessible for a limited time. Immunocore specializes in T cell receptor bispecific immunotherapies aimed at treating cancer and other diseases, with its lead product, KIMMTRAK, already FDA approved for a specific cancer type.

Immunocore announced its participation in the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, presenting updated overall survival data from the Phase 1b metastatic cutaneous melanoma trial. The company will deliver an oral presentation and two poster presentations during the event, scheduled from June 3-7, 2022. Key presentations include updated OS data for tebentafusp and its effects in metastatic uveal melanoma. The findings will be available for registered attendees on the ASCO website.

Medison Pharma announced a significant expansion of its partnership with Immunocore Holdings plc, extending their multi-territorial agreement to include Australia and New Zealand. This move increases Medison's global reach to 25 countries across four continents, bolstering its commercial offerings. The agreement aims to seek regulatory authorization for Immunocore's KIMMTRAK® to treat unresectable or metastatic uveal melanoma. The therapy is already approved in the US and EU, representing a key advancement in cancer treatment accessibility.

Acacia Research reported Q1 2022 financial results, achieving $13.5 million in total revenue, a significant increase from $5.8 million in Q1 2021. This included $10.9 million from Printronix, acquired in October 2021. The company recorded $66.9 million in realized gains, primarily from its Life Science Portfolio, and completed a $15 million share repurchase. However, Acacia faced a $73.3 million net loss due to unrealized losses totaling $(172.2 million). The current book value decreased to $7.42 per share.